Drug Profile


Alternative Names: CT-053; CT-053-PTSA; Ningetinib tosylate

Latest Information Update: 25 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HEC Pharm
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c met inhibitors; RON protein inhibitors; Signal transduction pathway modulators; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Non-small cell lung cancer
  • Discontinued Glioblastoma

Most Recent Events

  • 25 Apr 2017 Sunshine Lake Pharma plans a phase I trial for Acute myeloid leukaemia (Second-line therapy or greater) in China (PO) (NCT03125876)
  • 25 Aug 2016 Phase-I clinical trials in Acute myeloid leukaemia in China (PO) (HEC Pharm pipeline, August 2016)
  • 25 Aug 2016 Phase-I clinical trials in Non-small cell lung cancer in China (PO) (HEC Pharm pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top